Congenital heart disease (CHD) is the most common birth defect in the developed world and the number one cause of infant mortality. The data shows that wice as many children die from CHD than all childhood cancers combined. In this context, the organizing theme and focus of Polyvacular Corporation is the transformation of the care of children with congenital heart disease by addressing development of an entirely new generation of valves. In the forefront of the effort to improve the lives of these children, the firm has/is developing polymeric transcatheter valves (PTV) specifically for children. Such devices are easy to manufacture in pediatric and adult sizes; can be made expandable to accommodate the growth of afflicted children wit the critical impact of reducing the need for repeat open-heart surgeries. OUR MISSION Our aim is to transform the care of children with congenital heart disease by developing an entirely new generation of valves made of medical grade polymer devoid of any biological tissue. Commonly used valves thus far are made with biological tissue. Unfortunately, our immune system targets and destroys this biological tissue, sometimes rapidly, rendering the valve ineffective. Our approach will allow us to deliver these valves in a minimally invasive fashion, and extend the time between repeat open-heart surgeries.
